The Biopharmaceutical CMO and CRO Market is expected to register a CAGR of 5.8% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The report is segmented by Source (Mammalian, Non-Mammalian); Service Type (Contract Manufacturing, Contract Research); Product (Biologics, Biosimilars, Vaccines). The global analysis is further broken-down at regional level and major countries. The report offers the value in USD for the above analysis and segments
Purpose of the ReportThe report Biopharmaceutical CMO and CRO Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Biopharmaceutical CMO and CRO Market Segmentation
Source- Mammalian
- Non-Mammalian
- Contract Manufacturing
- Contract Research
- Biologics
- Biosimilars
- Vaccines
- North America
- Europe
- Asia-Pacific
- South and Central America
- Middle East and Africa
Strategic Insights
Biopharmaceutical CMO and CRO Market Growth Drivers- Rising Demand for Biopharmaceuticals and Biologics: The growing prevalence of chronic diseases such as cancer, diabetes, autoimmune disorders, and cardiovascular diseases has led to increased demand for biopharmaceutical products, such as monoclonal antibodies, vaccines, gene therapies, and others. Biologics, in particular, require specialized manufacturing processes, which CMOs are well-equipped to handle.
- Advancements in Biotechnology and Drug Discovery: Advances in biotechnology, including next-generation sequencing (NGS), CRISPR, and personalized medicine, are creating new avenues for drug development. These advanced techniques require specialized expertise and infrastructure that CMOs and CROs can provide.
- Increased Outsourcing of Early-Stage Drug Development: Early stage outsourcing development refers to the practice of delegating specific business processes or functions to external service providers during the initial phases of a project or startup. This strategy allows organizations to focus on core competencies while leveraging the expertise of specialized vendors to enhance efficiency and reduce costs. Biopharmaceutical companies are increasingly outsourcing early-stage drug development activities, including preclinical testing, discovery, and Phase I/II clinical trials, to specialized CROs. This trend will drive market growth.
- Shift Toward Digitalization and Automation in Drug Development: Automation and digital technologies, such as AI, machine learning, and blockchain, are transforming the biopharmaceutical R&D and manufacturing landscape. CROs and CMOs are increasingly leveraging these technologies to enhance data analysis, clinical trial management, and manufacturing processes, ultimately leading to faster and more efficient drug development.
- Expanding Biologics Manufacturing Capabilities: The growth of the biologics market offers substantial opportunities as demand for innovative therapies surges. Expanding manufacturing capabilities allows companies to scale production of complex biologics, such as monoclonal antibodies and gene therapies. Advancements in bioprocessing technologies, coupled with increased investment in facilities, enable faster development timelines and improved product quality, driving competitive advantage and market share expansion.
- Acquisitions and Partnerships: Acquisitions and partnerships in biologics manufacturing present lucrative opportunities for companies seeking to enhance their capabilities and market reach. Collaborating with established manufacturers or acquiring innovative firms allows organizations to leverage advanced technologies, streamline production processes, and access new markets. These strategic moves can accelerate development timelines, foster innovation, and ultimately strengthen competitive positioning in the growing biologics sector.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Biopharmaceutical CMO and CRO Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Biopharmaceutical CMO and CRO Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Some of the customization options available based on the request are an additional 3-5 company profiles and country-specific analysis of 3-5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation# as our team would review the same and check the feasibility
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request
Rising demand for biopharmaceuticals and biologics, and advancements in biotechnology and drug discovery are the major factors driving the biopharmaceutical CMO and CRO market.
increased outsourcing of early-stage drug development and shift toward digitalization and automation in drug development are likely to remain a key trend in the market.
The Biopharmaceutical CMO and CRO Market is estimated to witness a CAGR of 5.8% from 2023 to 2031
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Biopharmaceutical CMO And CRO Market - By Source
1.3.2 Biopharmaceutical CMO And CRO Market - By Service Type
1.3.3 Biopharmaceutical CMO And CRO Market - By Product
1.3.4 Biopharmaceutical CMO And CRO Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. BIOPHARMACEUTICAL CMO AND CRO MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PORTER'S FIVE FORCES ANALYSIS
4.2.1 Bargaining Power of Buyers
4.2.1 Bargaining Power of Suppliers
4.2.1 Threat of Substitute
4.2.1 Threat of New Entrants
4.2.1 Competitive Rivalry
4.3. EXPERT OPINIONS
5. BIOPHARMACEUTICAL CMO AND CRO MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. BIOPHARMACEUTICAL CMO AND CRO MARKET - GLOBAL MARKET ANALYSIS
6.1. BIOPHARMACEUTICAL CMO AND CRO - GLOBAL MARKET OVERVIEW
6.2. BIOPHARMACEUTICAL CMO AND CRO - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. BIOPHARMACEUTICAL CMO AND CRO MARKET - REVENUE AND FORECASTS TO 2028 - SOURCE
7.1. OVERVIEW
7.2. SOURCE MARKET FORECASTS AND ANALYSIS
7.3. MAMMALIAN
7.3.1. Overview
7.3.2. Mammalian Market Forecast and Analysis
7.4. NON-MAMMALIAN
7.4.1. Overview
7.4.2. Non-Mammalian Market Forecast and Analysis
8. BIOPHARMACEUTICAL CMO AND CRO MARKET - REVENUE AND FORECASTS TO 2028 - SERVICE TYPE
8.1. OVERVIEW
8.2. SERVICE TYPE MARKET FORECASTS AND ANALYSIS
8.3. CONTRACT MANUFACTURING
8.3.1. Overview
8.3.2. Contract Manufacturing Market Forecast and Analysis
8.3.3. Analytical and QC studies Market
8.3.3.1. Overview
8.3.3.2. Analytical and QC studies Market Forecast and Analysis
8.3.4. Fill and Finish Operations Market
8.3.4.1. Overview
8.3.4.2. Fill and Finish Operations Market Forecast and Analysis
8.3.5. Packaging Market
8.3.5.1. Overview
8.3.5.2. Packaging Market Forecast and Analysis
8.3.6. Process Development Market
8.3.6.1. Overview
8.3.6.2. Process Development Market Forecast and Analysis
8.4. CONTRACT RESEARCH
8.4.1. Overview
8.4.2. Contract Research Market Forecast and Analysis
8.4.3. Cardiology Market
8.4.3.1. Overview
8.4.3.2. Cardiology Market Forecast and Analysis
8.4.4. Inflammation and Immunology Market
8.4.4.1. Overview
8.4.4.2. Inflammation and Immunology Market Forecast and Analysis
8.4.5. Neuroscience Market
8.4.5.1. Overview
8.4.5.2. Neuroscience Market Forecast and Analysis
8.4.6. Oncology Market
8.4.6.1. Overview
8.4.6.2. Oncology Market Forecast and Analysis
8.4.7. Other Types Market
8.4.7.1. Overview
8.4.7.2. Other Types Market Forecast and Analysis
9. BIOPHARMACEUTICAL CMO AND CRO MARKET - REVENUE AND FORECASTS TO 2028 - PRODUCT
9.1. OVERVIEW
9.2. PRODUCT MARKET FORECASTS AND ANALYSIS
9.3. BIOLOGICS
9.3.1. Overview
9.3.2. Biologics Market Forecast and Analysis
9.3.3. Antisense RNAi Market
9.3.3.1. Overview
9.3.3.2. Antisense RNAi Market Forecast and Analysis
9.3.4. and Molecular Therapy Market
9.3.4.1. Overview
9.3.4.2. and Molecular Therapy Market Forecast and Analysis
9.3.5. Monoclonal Antibodies (MAbs) Market
9.3.5.1. Overview
9.3.5.2. Monoclonal Antibodies (MAbs) Market Forecast and Analysis
9.3.6. Recombinant Proteins Market
9.3.6.1. Overview
9.3.6.2. Recombinant Proteins Market Forecast and Analysis
9.3.7. Vaccines Market
9.3.7.1. Overview
9.3.7.2. Vaccines Market Forecast and Analysis
9.3.8. Other Biologics Market
9.3.8.1. Overview
9.3.8.2. Other Biologics Market Forecast and Analysis
9.4. BIOSIMILARS
9.4.1. Overview
9.4.2. Biosimilars Market Forecast and Analysis
10. BIOPHARMACEUTICAL CMO AND CRO MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Biopharmaceutical CMO And CRO Market Overview
10.1.2 North America Biopharmaceutical CMO And CRO Market Forecasts and Analysis
10.1.3 North America Biopharmaceutical CMO And CRO Market Forecasts and Analysis - By Source
10.1.4 North America Biopharmaceutical CMO And CRO Market Forecasts and Analysis - By Service Type
10.1.5 North America Biopharmaceutical CMO And CRO Market Forecasts and Analysis - By Product
10.1.6 North America Biopharmaceutical CMO And CRO Market Forecasts and Analysis - By Countries
10.1.6.1 United States Biopharmaceutical CMO And CRO Market
10.1.6.1.1 United States Biopharmaceutical CMO And CRO Market by Source
10.1.6.1.2 United States Biopharmaceutical CMO And CRO Market by Service Type
10.1.6.1.3 United States Biopharmaceutical CMO And CRO Market by Product
10.1.6.2 Canada Biopharmaceutical CMO And CRO Market
10.1.6.2.1 Canada Biopharmaceutical CMO And CRO Market by Source
10.1.6.2.2 Canada Biopharmaceutical CMO And CRO Market by Service Type
10.1.6.2.3 Canada Biopharmaceutical CMO And CRO Market by Product
10.1.6.3 Mexico Biopharmaceutical CMO And CRO Market
10.1.6.3.1 Mexico Biopharmaceutical CMO And CRO Market by Source
10.1.6.3.2 Mexico Biopharmaceutical CMO And CRO Market by Service Type
10.1.6.3.3 Mexico Biopharmaceutical CMO And CRO Market by Product
10.2. EUROPE
10.2.1 Europe Biopharmaceutical CMO And CRO Market Overview
10.2.2 Europe Biopharmaceutical CMO And CRO Market Forecasts and Analysis
10.2.3 Europe Biopharmaceutical CMO And CRO Market Forecasts and Analysis - By Source
10.2.4 Europe Biopharmaceutical CMO And CRO Market Forecasts and Analysis - By Service Type
10.2.5 Europe Biopharmaceutical CMO And CRO Market Forecasts and Analysis - By Product
10.2.6 Europe Biopharmaceutical CMO And CRO Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Biopharmaceutical CMO And CRO Market
10.2.6.1.1 Germany Biopharmaceutical CMO And CRO Market by Source
10.2.6.1.2 Germany Biopharmaceutical CMO And CRO Market by Service Type
10.2.6.1.3 Germany Biopharmaceutical CMO And CRO Market by Product
10.2.6.2 France Biopharmaceutical CMO And CRO Market
10.2.6.2.1 France Biopharmaceutical CMO And CRO Market by Source
10.2.6.2.2 France Biopharmaceutical CMO And CRO Market by Service Type
10.2.6.2.3 France Biopharmaceutical CMO And CRO Market by Product
10.2.6.3 Italy Biopharmaceutical CMO And CRO Market
10.2.6.3.1 Italy Biopharmaceutical CMO And CRO Market by Source
10.2.6.3.2 Italy Biopharmaceutical CMO And CRO Market by Service Type
10.2.6.3.3 Italy Biopharmaceutical CMO And CRO Market by Product
10.2.6.4 Spain Biopharmaceutical CMO And CRO Market
10.2.6.4.1 Spain Biopharmaceutical CMO And CRO Market by Source
10.2.6.4.2 Spain Biopharmaceutical CMO And CRO Market by Service Type
10.2.6.4.3 Spain Biopharmaceutical CMO And CRO Market by Product
10.2.6.5 United Kingdom Biopharmaceutical CMO And CRO Market
10.2.6.5.1 United Kingdom Biopharmaceutical CMO And CRO Market by Source
10.2.6.5.2 United Kingdom Biopharmaceutical CMO And CRO Market by Service Type
10.2.6.5.3 United Kingdom Biopharmaceutical CMO And CRO Market by Product
10.2.6.6 Rest of Europe Biopharmaceutical CMO And CRO Market
10.2.6.6.1 Rest of Europe Biopharmaceutical CMO And CRO Market by Source
10.2.6.6.2 Rest of Europe Biopharmaceutical CMO And CRO Market by Service Type
10.2.6.6.3 Rest of Europe Biopharmaceutical CMO And CRO Market by Product
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Biopharmaceutical CMO And CRO Market Overview
10.3.2 Asia-Pacific Biopharmaceutical CMO And CRO Market Forecasts and Analysis
10.3.3 Asia-Pacific Biopharmaceutical CMO And CRO Market Forecasts and Analysis - By Source
10.3.4 Asia-Pacific Biopharmaceutical CMO And CRO Market Forecasts and Analysis - By Service Type
10.3.5 Asia-Pacific Biopharmaceutical CMO And CRO Market Forecasts and Analysis - By Product
10.3.6 Asia-Pacific Biopharmaceutical CMO And CRO Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Biopharmaceutical CMO And CRO Market
10.3.6.1.1 Australia Biopharmaceutical CMO And CRO Market by Source
10.3.6.1.2 Australia Biopharmaceutical CMO And CRO Market by Service Type
10.3.6.1.3 Australia Biopharmaceutical CMO And CRO Market by Product
10.3.6.2 China Biopharmaceutical CMO And CRO Market
10.3.6.2.1 China Biopharmaceutical CMO And CRO Market by Source
10.3.6.2.2 China Biopharmaceutical CMO And CRO Market by Service Type
10.3.6.2.3 China Biopharmaceutical CMO And CRO Market by Product
10.3.6.3 India Biopharmaceutical CMO And CRO Market
10.3.6.3.1 India Biopharmaceutical CMO And CRO Market by Source
10.3.6.3.2 India Biopharmaceutical CMO And CRO Market by Service Type
10.3.6.3.3 India Biopharmaceutical CMO And CRO Market by Product
10.3.6.4 Japan Biopharmaceutical CMO And CRO Market
10.3.6.4.1 Japan Biopharmaceutical CMO And CRO Market by Source
10.3.6.4.2 Japan Biopharmaceutical CMO And CRO Market by Service Type
10.3.6.4.3 Japan Biopharmaceutical CMO And CRO Market by Product
10.3.6.5 South Korea Biopharmaceutical CMO And CRO Market
10.3.6.5.1 South Korea Biopharmaceutical CMO And CRO Market by Source
10.3.6.5.2 South Korea Biopharmaceutical CMO And CRO Market by Service Type
10.3.6.5.3 South Korea Biopharmaceutical CMO And CRO Market by Product
10.3.6.6 Rest of Asia-Pacific Biopharmaceutical CMO And CRO Market
10.3.6.6.1 Rest of Asia-Pacific Biopharmaceutical CMO And CRO Market by Source
10.3.6.6.2 Rest of Asia-Pacific Biopharmaceutical CMO And CRO Market by Service Type
10.3.6.6.3 Rest of Asia-Pacific Biopharmaceutical CMO And CRO Market by Product
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Biopharmaceutical CMO And CRO Market Overview
10.4.2 Middle East and Africa Biopharmaceutical CMO And CRO Market Forecasts and Analysis
10.4.3 Middle East and Africa Biopharmaceutical CMO And CRO Market Forecasts and Analysis - By Source
10.4.4 Middle East and Africa Biopharmaceutical CMO And CRO Market Forecasts and Analysis - By Service Type
10.4.5 Middle East and Africa Biopharmaceutical CMO And CRO Market Forecasts and Analysis - By Product
10.4.6 Middle East and Africa Biopharmaceutical CMO And CRO Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Biopharmaceutical CMO And CRO Market
10.4.6.1.1 South Africa Biopharmaceutical CMO And CRO Market by Source
10.4.6.1.2 South Africa Biopharmaceutical CMO And CRO Market by Service Type
10.4.6.1.3 South Africa Biopharmaceutical CMO And CRO Market by Product
10.4.6.2 Saudi Arabia Biopharmaceutical CMO And CRO Market
10.4.6.2.1 Saudi Arabia Biopharmaceutical CMO And CRO Market by Source
10.4.6.2.2 Saudi Arabia Biopharmaceutical CMO And CRO Market by Service Type
10.4.6.2.3 Saudi Arabia Biopharmaceutical CMO And CRO Market by Product
10.4.6.3 U.A.E Biopharmaceutical CMO And CRO Market
10.4.6.3.1 U.A.E Biopharmaceutical CMO And CRO Market by Source
10.4.6.3.2 U.A.E Biopharmaceutical CMO And CRO Market by Service Type
10.4.6.3.3 U.A.E Biopharmaceutical CMO And CRO Market by Product
10.4.6.4 Rest of Middle East and Africa Biopharmaceutical CMO And CRO Market
10.4.6.4.1 Rest of Middle East and Africa Biopharmaceutical CMO And CRO Market by Source
10.4.6.4.2 Rest of Middle East and Africa Biopharmaceutical CMO And CRO Market by Service Type
10.4.6.4.3 Rest of Middle East and Africa Biopharmaceutical CMO And CRO Market by Product
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Biopharmaceutical CMO And CRO Market Overview
10.5.2 South and Central America Biopharmaceutical CMO And CRO Market Forecasts and Analysis
10.5.3 South and Central America Biopharmaceutical CMO And CRO Market Forecasts and Analysis - By Source
10.5.4 South and Central America Biopharmaceutical CMO And CRO Market Forecasts and Analysis - By Service Type
10.5.5 South and Central America Biopharmaceutical CMO And CRO Market Forecasts and Analysis - By Product
10.5.6 South and Central America Biopharmaceutical CMO And CRO Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Biopharmaceutical CMO And CRO Market
10.5.6.1.1 Brazil Biopharmaceutical CMO And CRO Market by Source
10.5.6.1.2 Brazil Biopharmaceutical CMO And CRO Market by Service Type
10.5.6.1.3 Brazil Biopharmaceutical CMO And CRO Market by Product
10.5.6.2 Argentina Biopharmaceutical CMO And CRO Market
10.5.6.2.1 Argentina Biopharmaceutical CMO And CRO Market by Source
10.5.6.2.2 Argentina Biopharmaceutical CMO And CRO Market by Service Type
10.5.6.2.3 Argentina Biopharmaceutical CMO And CRO Market by Product
10.5.6.3 Rest of South and Central America Biopharmaceutical CMO And CRO Market
10.5.6.3.1 Rest of South and Central America Biopharmaceutical CMO And CRO Market by Source
10.5.6.3.2 Rest of South and Central America Biopharmaceutical CMO And CRO Market by Service Type
10.5.6.3.3 Rest of South and Central America Biopharmaceutical CMO And CRO Market by Product
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. BIOPHARMACEUTICAL CMO AND CRO MARKET, KEY COMPANY PROFILES
12.1. AGC BIOLOGICS
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. BOEHRINGER INGELHEIM INTERNATIONAL GMBH
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. FUJIFILM DIOSYNTH BIOTECHNOLOGIES U.S.A., INC.
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. TOYOBO CO., LTD
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. JRS PHARMA
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. LONZA
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. PRA HEALTH SCIENCES, INC.
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. PROBIOGEN AG
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. RENTSCHLER BIOPHARMA SE
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. SAMSUNG BIOLOGICS
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
1. AGC Biologics
2. Boehringer Ingelheim International GmbH
3. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
4. TOYOBO CO., LTD
5. JRS PHARMA
6. Lonza
7. PRA Health Sciences, Inc.
8. ProBioGen AG
9. Rentschler Biopharma SE
10. Samsung BioLogics
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For